GlassScriptPhysician profile
Heather Partridge
NPI 1972144152
$1,580.56
in general payments reported to CMS, 2019-2025
23 companies · $579 in 2025
The $579 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $442 · 2023: $504 · 2024: $55.33 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $440.62 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $172.66 | 2022-2025 | Farxiga, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $144.32 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $127.57 | 2022-2025 | |
| Esperion Therapeutics, INC. | $114.42 | 2022-2025 | Nexletol |
| Amgen INC. | $81.07 | 2022-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $64.08 | 2022-2025 | Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $62.95 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $60.29 | 2023-2025 | |
| Exact Sciences Corporation | $50.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $45.07 | 2022-2025 | Korlym |
| Abbott Laboratories | $24.38 | 2025 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $21.13 | 2024 | Horizant |
| Amarin Pharma, INC. | $21.09 | 2022 | |
| Phadia US INC. | $19.22 | 2024 | Immunocap |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.69 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.79 | 2025 | Xifaxan |
| Ethicon US, LLC | $15.98 | 2022 | |
| Boston Scientific Corporation | $14.98 | 2024 | |
| Abbvie INC. | $14.62 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Partridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.